CytoImmune Therapeutics
↗Duarte, USA
CytoImmune Therapeutics is a clinical-stage immuno-oncology company specializing in the development of novel engineered natural killer (NK) cell therapies for cancer. The company utilizes proprietary platforms, including TRACK-NK™ (Tumor-Reactive and Anti-PD-L1 Co-stimulated Killer) and CoalesceNT™, to create 'off-the-shelf' allogeneic therapies that both directly attack tumor cells and stimulate the patient's own adaptive immune system through secreted cytokines like IL-15.
In addition to its therapeutic pipeline, CytoImmune operates a significant biopharmaceutical manufacturing complex in Toa Baja, Puerto Rico. This facility provides end-to-end clinical manufacturing and process development services for its internal programs and external partners, positioning the company as both a drug developer and a boutique CDMO for advanced cell and viral vector therapies.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:$1M-$10M
Founded:2017
Ownership:private
Status:operating
FUNDING
Stage:Series C
Total Raised:$37.5M
Investors:Myeloma Investment Fund, Sofinnova Partners, Richard Santulli
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1
Modalities:Cell therapy, CAR-NK, mAb, Bispecific antibodies
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:CytoImmune Therapeutics Puerto Rico LLC, CytoImmune Australia Pty Ltd
Key Partnerships:Roche: Supply agreement for atezolizumab (Tecentriq) for CYTO-102 combination trials, City of Hope: Licensing and research collaboration, Hemostemix: Manufacturing services agreement for ACP-01 production, Matica Biotechnology: Collaboration on viral vector manufacturing, Chan Soon-Shiong Institute for Medicine: Clinical trial site partnership
COMPETITION
Position:Emerging
Competitors:Fate Therapeutics, Nkarta Therapeutics, Shoreline Biosciences, Dragonfly Therapeutics, Artiva Biotherapeutics
LEADERSHIP
Key Executives:
José Eduardo Vidal, Ph.D. - CEO
Michael A. Caligiuri, M.D. - Co-Founder & CSO
Yulii Bogatyrenko - Chief Business Officer
Scientific Founders:Michael A. Caligiuri, M.D., Jianhua Yu, Ph.D.
Board Members:Richard T. Santulli (Chairman), Graeme Bell, José Eduardo Vidal, Michael A. Caligiuri
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with CytoImmune Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.